Monday, August 21, 2023 9:19:54 AM
Community
Markets
News
Portfolio
DealRoom
Search Companies, etc
News Press Releases
Grabar Law Office Investigates Claims on Behalf of Shareholders of Ardelyx Inc. (ARDX)
ARDX | 9 minutes ago
Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2023) - A securities class action complaint alleges that Ardelyx Inc. (NASDAQ: ARDX), via certain of its officers, made materially false and misleading statements regarding tenapanor and the likelihood that it would be approved by the FDA, which led investors to suffer significant losses.
Specifically, it is alleged that on or about June 30, 2020, Ardelyx submitted a New Drug Application ("NDA") to the FDA to obtain approval to sell and market tenapanor for the treatment of hyperphosphatemia in adult CKD patients on dialysis. Because Defendants considered tenapanor their leading product candidate, the fate of Ardelyx's tenapanor NDA - i.e., whether the FDA would approve or reject it - was integral to the valuation and future success of Ardelyx securities.
Although Defendants repeatedly assured the market that the FDA's approval was all but guaranteed because the FDA had already seen some of the data and because the Company's meetings with the FDA were going well, in fact as early as March 2020 the FDA had raised substantial concerns that Ardelyx's clinical trial data had not shown a sufficiently quantifiable clinical benefit of administering tenapanor to treat hyperphosphatemia in adult CKD patients on dialysis. Then, on July 19, 2021, the Company announced that the FDA had rejected the tenapanor NDA for the exact reasons the FDA outlined in the March 2020 meeting.
Current Ardelyx shareholders who have held Ardelyx shares since on or before March 6, 2020, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to contact us at jgrabar@grabarlaw.com, visit https://grabarlaw.com/the-latest/ardelyx-shareholder-investigation/, or call 267-507-6085.
Recent ARDX News
- Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:02:28 PM
- Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024 • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Ardelyx, Inc. Reports Employment Inducement Grants • GlobeNewswire Inc. • 03/28/2024 08:05:00 PM
- Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Ardelyx, Inc. Reports Employment Inducement Grants • GlobeNewswire Inc. • 03/12/2024 08:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:21:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 11:57:56 PM
- Ardelyx to Participate at the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 01:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 11:30:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 10:01:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:58:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:56:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:56:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:56:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:40:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:04:01 PM
- Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/22/2024 09:01:00 PM
- U.S. Futures Surge on Nvidia’s Stellar Performance, Global Markets Respond Positively • IH Market News • 02/22/2024 11:05:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/13/2024 07:12:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:14:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/08/2024 09:32:26 PM
- Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 • GlobeNewswire Inc. • 02/01/2024 01:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:39:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:38:09 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM